A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: AL101
Sponsor: Ayala Pharmaceuticals, Inc,